TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
TFF Pharmaceuticals (NASDAQ: TFFP), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel. Dr. Harlan Weisman, CEO of TFF Pharmaceuticals, will present a corporate overview on September 9, 2024, available on-demand starting at 7:00 AM Eastern Time.
Investors can access the presentation webcast through the company's investor relations website. The replay will be available for approximately 90 days after the event. Additionally, Dr. Weisman and Kirk Coleman, CFO, will be available for one-on-one meetings throughout the conference. TFF Pharmaceuticals focuses on developing innovative drug products using its patented Thin Film Freezing technology platform.
TFF Pharmaceuticals (NASDAQ: TFFP), una compagnia biofarmaceutica in fase clinica, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. L'evento si terrà dal 9 all'11 settembre 2024, presso il Lotte New York Palace Hotel. Dr. Harlan Weisman, CEO di TFF Pharmaceuticals, presenterà una panoramica aziendale il 9 settembre 2024, disponibile on-demand a partire dalle 7:00 AM ora orientale.
Gli investitori possono accedere alla presentazione attraverso il sito web delle relazioni con gli investitori dell'azienda. La registrazione sarà disponibile per circa 90 giorni dopo l'evento. Inoltre, Dr. Weisman e Kirk Coleman, CFO, saranno disponibili per incontri individuali durante tutta la conferenza. TFF Pharmaceuticals si concentra sullo sviluppo di prodotti farmaceutici innovativi utilizzando la sua piattaforma tecnologica brevettata Thin Film Freezing.
TFF Pharmaceuticals (NASDAQ: TFFP), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright. El evento se llevará a cabo del 9 al 11 de septiembre de 2024, en el Lotte New York Palace Hotel. Dr. Harlan Weisman, CEO de TFF Pharmaceuticals, presentará una visión general de la empresa el 9 de septiembre de 2024, disponible bajo demanda a partir de las 7:00 AM hora del este.
Los inversores pueden acceder a la transmisión de la presentación a través del sitio web de relaciones con inversores de la empresa. La repetición estará disponible durante aproximadamente 90 días después del evento. Además, Dr. Weisman y Kirk Coleman, CFO, estarán disponibles para reuniones uno a uno durante toda la conferencia. TFF Pharmaceuticals se enfoca en desarrollar productos farmacéuticos innovadores utilizando su plataforma tecnológica patentada Thin Film Freezing.
TFF 제약회사 (NASDAQ: TFFP)는 임상 단계의 생물의약품 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 롯데 뉴욕 팰리스 호텔에서 열립니다. Dr. Harlan Weisman TFF 제약회사의 CEO가 2024년 9월 9일에 기업 개요를 발표할 예정이며, 동부 표준시 기준으로 오전 7시부터 주문형으로 제공됩니다.
투자자들은 회사의 투자자 관계 웹사이트를 통해 발표 웹캐스트에 액세스할 수 있습니다. 재생은 행사 후 약 90일 동안 제공될 예정입니다. 또한 Dr. Weisman과 Kirk Coleman, CFO는 컨퍼런스 기간 동안 일대일 회의에 참석할 수 있습니다. TFF 제약회사는 특허 받은 Thin Film Freezing 기술 플랫폼을 사용하여 혁신적인 약물 제품 개발에 주력하고 있습니다.
TFF Pharmaceuticals (NASDAQ: TFFP), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'événement est prévu du 9 au 11 septembre 2024 à l'hôtel Lotte New York Palace. Dr. Harlan Weisman, PDG de TFF Pharmaceuticals, présentera un aperçu de l'entreprise le 9 septembre 2024, accessible à la demande à partir de 7h00, heure de l'Est.
Les investisseurs peuvent accéder à la diffusion de la présentation via le site web des relations avec les investisseurs de l'entreprise. La rediffusion sera disponible pendant environ 90 jours après l'événement. De plus, Dr. Weisman et Kirk Coleman, CFO, seront disponibles pour des réunions individuelles tout au long de la conférence. TFF Pharmaceuticals se concentre sur le développement de produits pharmaceutiques innovants en utilisant sa plateforme technologique brevetée Thin Film Freezing.
TFF Pharmaceuticals (NASDAQ: TFFP), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet vom 9. bis 11. September 2024 im Lotte New York Palace Hotel statt. Dr. Harlan Weisman, CEO von TFF Pharmaceuticals, wird am 9. September 2024 eine Unternehmensübersicht präsentieren, die ab 7:00 Uhr Eastern Time on-demand verfügbar sein wird.
Investoren können über die Investor-Relations-Website des Unternehmens auf den Präsentations-Webcast zugreifen. Der Replay wird ungefähr 90 Tage nach der Veranstaltung verfügbar sein. Darüber hinaus stehen Dr. Weisman und Kirk Coleman, CFO, während der gesamten Konferenz für Einzelgespräche zur Verfügung. TFF Pharmaceuticals konzentriert sich auf die Entwicklung innovativer Arzneimittelprodukte mit seiner patentierten Thin Film Freezing-Technologieplattform.
- None.
- None.
FORT WORTH, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Dr. Harlan Weisman, CEO, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel.
| Presentation Date: | September 9, 2024 |
| Time: | Available on-demand starting at 7:00 AM Eastern Time |
| Webcast Link: | https://journey.ct.events/view/2ab5063d-1d8d-4439-8667-a87907f48d97 |
A webcast of the presentation can be accessed on the investor relations section of the TFF Pharmaceuticals website. A replay of the webcast will be archived and available following the event for approximately 90 days.
https://tffpharma.com/investors/
Dr. Weisman and Kirk Coleman, CFO will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click below:
https://hcwevents.com/annualconference/
ABOUT TFF PHARMACEUTICALS’ THIN FILM FREEZING (TFF) TECHNOLOGY
TFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The TFF process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy. The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders created by TFF can deliver as much as
ABOUT TFF PHARMACEUTICALS
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety, and stability. The company’s versatile TFF technology platform has broad applicability to convert most any drug, including vaccines, small and large molecules, and biologics, into an elegant dry powder highly advantageous for inhalation or for topical delivery to the eyes, nose and skin.
SAFE HARBOR
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including (i) the risk that further data from the Company’s ongoing Phase 2 trial of TFF TAC may not be consistent with the positive preliminary data obtained to date, (ii) the risk that the Company may not be able to obtain additional working capital with which to continue its current operations and clinical trials as and when needed, (iii) success in early phases of pre-clinical and clinical trials do not ensure later clinical trials will be successful; (iv) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (v) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, and (vi) those other risks disclosed in the section “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2024. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.
Investor Relations Contact:
Jason Nelson
CoreIR
jason@coreir.com
FAQ
When is TFF Pharmaceuticals (TFFP) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for TFF Pharmaceuticals (TFFP) at the H.C. Wainwright conference?
Where can investors access the webcast of TFF Pharmaceuticals' (TFFP) presentation?
How long will the replay of TFF Pharmaceuticals' (TFFP) presentation be available?
What is the main focus of TFF Pharmaceuticals (TFFP)?
